COLISTIN HIKMA Powder for solution for IV injection or inhalation (by nebulization)
Colistin (Colistimethate Sodium)
1 MIU
Hikma Pharmaceuticals
| Pack size | 1 Glass Vial (10ml) |
|---|---|
| Dispensing mode | POM |
| Source | JORDAN |
| Agent | ALPHAMED CO. (AUH) LTD. |
| Retail Price | 16.50 AED |
Indications
COLISTIN HIKMA Powder for solution for IV injection or inhalation (by nebulization) is used for:
Bowel sterilization, gastrointestinal tract infections, respiratory tract infections
Adult Dose
Oral
Bowel sterilisation; Gastrointestinal infections
Adult: As colistin sulfate: 1.5-3 MIU tid.
Child: As colistin sulfate: <15 kg: Not suitable; 15-30 kg: 0.75-1.5 MIU tid.
Parenteral
Severe Gram-negative infections
Adult: As colistimethate Na (strength expressed in terms of colistin base): 2.5-5 mg/kg/day in 2-4 divided doses. Max: 5 mg/kg/day.
Inhalation
Adjunct to antimicrobial therapy in resp infections As colistimethate Na: 1-2 million units twice daily. Max: 2 million units 3 times/day for up to 3 mth in frequent recurrent infections.
Child Dose
Oral
Bowel sterilisation; Gastrointestinal infections
Child: As colistin sulfate: <15 kg: Not suitable; 15-30 kg: 0.75-1.5 MIU tid.
Parenteral
Severe Gram-negative infections
Child: IV, IM 2.5–5 mg base/kg/day based on IBW q8h
Up to 5–7 mg base/kg/day
Renal Dose
Renal impairment:
CrCl (ml/min)
20-50 1-2 million units every 8 hr.
10-20 1 million units every 12-18 hr.
<10 1 million units every 18-24 hr
Administration
Reconstitution: Reconstitute 150 mg vial w/ 2 mL sterile water for inj. Reconstituted soln provides colistimethate Na at a concentration equivalent to 75 mg/mL colistin base.
IV/IM Administration
IM or
IV push: half of daily dose injected over 3-5 min q12 hr
IV infusion: half of daily dose injected over 3-5 min; other half mixed with compatible IV solution and administered 1-2 hr later at 5-6 mg/hr
Contra Indications
Hypersensitivity. Anuria; porphyria; myasthenia gravis. Pregnancy and lactation.
Precautions
Preexisting renal impairment; disorders of neuromuscular transmission. Monitor serum creatinine and BUN regularly while on treatment.
Lactation: unknown; use caution
Pregnancy-Lactation
Pregnancy Category: C
Lactation: unknown; use caution
Interactions
Potentiates chloramphenicol and trimethoprim.
Potentially Fatal: Potentiates action of curariform muscle relaxants. Potentiates nephrotoxicity of aminoglycosides and cephalothin.
Adverse Effects
Side effects of Colistin (Colistimethate Sodium) :
1-10%
Dizziness, Paresthesia, tingling sensation
<1%
Neurotoxicity, Nephrotoxicity, Acute respiratory failure (inhalation route), Respiratory tract paralysis
Potentially Fatal: Acute tubular necrosis, neurotoxicity; nephrotoxicity. The neuromuscular blockade is potentially fatal, when associated with use of curariform muscle relaxants.
Mechanism of Action
Colistin sulfate is a polymyxin antibiotic which is active against aerobic gram-negative bacteria including most enterobacteria except Proteus, Providentia and Serratia. Susceptible organisms include P. aeruginosa, Legionella spp, H. influenzae, Acinetobacter, V. cholera, Salmonella, Shigella and Pasteurella.
Colistin sulfate is used orally while colistimethate sodium is used parenterally or via inhalational route.
Note
COLISTIN HIKMA 1 MIU Powder for solution for IV injection or inhalation (by nebulization) manufactured by Hikma Pharmaceuticals. Its generic name is Colistin (Colistimethate Sodium). COLISTIN HIKMA is availble in United Arab Emirates.
Farmaco UAE drug index information on COLISTIN HIKMA Powder for solution for IV injection or inhalation (by nebulization) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.